Literature DB >> 26292178

Individual cognitive stimulation therapy for dementia: a clinical effectiveness and cost-effectiveness pragmatic, multicentre, randomised controlled trial.

Vasiliki Orgeta1, Phuong Leung1, Lauren Yates1,2, Sujin Kang3, Zoe Hoare3, Catherine Henderson4, Chris Whitaker3, Alistair Burns5, Martin Knapp4, Iracema Leroi5, Esme D Moniz-Cook6, Stephen Pearson7, Stephen Simpson8, Aimee Spector9, Steven Roberts10, Ian T Russell11, Hugo de Waal12,13, Robert T Woods14, Martin Orrell2.   

Abstract

BACKGROUND: Group cognitive stimulation therapy programmes can benefit cognition and quality of life for people with dementia. Evidence for home-based, carer-led cognitive stimulation interventions is limited.
OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of carer-delivered individual cognitive stimulation therapy (iCST) for people with dementia and their family carers, compared with treatment as usual (TAU).
DESIGN: A multicentre, single-blind, randomised controlled trial assessing clinical effectiveness and cost-effectiveness. Assessments were at baseline, 13 weeks and 26 weeks (primary end point).
SETTING: Participants were recruited through Memory Clinics and Community Mental Health Teams for older people. PARTICIPANTS: A total of 356 caregiving dyads were recruited and 273 completed the trial. INTERVENTION: iCST consisted of structured cognitive stimulation sessions for people with dementia, completed up to three times weekly over 25 weeks. Family carers were supported to deliver the sessions at home. MAIN OUTCOME MEASURES: Primary outcomes for the person with dementia were cognition and quality of life. Secondary outcomes included behavioural and psychological symptoms, activities of daily living, depressive symptoms and relationship quality. The primary outcome for the family carers was mental/physical health (Short Form questionnaire-12 items). Health-related quality of life (European Quality of Life-5 Dimensions), mood symptoms, resilience and relationship quality comprised the secondary outcomes. Costs were estimated from health and social care and societal perspectives.
RESULTS: There were no differences in any of the primary outcomes for people with dementia between intervention and TAU [cognition: mean difference -0.55, 95% confidence interval (CI) -2.00 to 0.90; p-value = 0.45; self-reported quality of life: mean difference -0.02, 95% CI -1.22 to 0.82; p-value = 0.97 at the 6-month follow-up]. iCST did not improve mental/physical health for carers. People with dementia in the iCST group experienced better relationship quality with their carer, but there was no evidence that iCST improved their activities of daily living, depression or behavioural and psychological symptoms. iCST seemed to improve health-related quality of life for carers but did not benefit carers' resilience or their relationship quality with their relative. Carers conducting more sessions had fewer depressive symptoms. Qualitative data suggested that people with dementia and their carers experienced better communication owing to iCST. Adjusted mean costs were not significantly different between the groups. From the societal perspective, both health gains and cost savings were observed.
CONCLUSIONS: iCST did not improve cognition or quality of life for people with dementia, or carers' physical and mental health. Costs of the intervention were offset by some reductions in social care and other services. Although there was some evidence of improvement in terms of the caregiving relationship and carers' health-related quality of life, iCST does not appear to deliver clinical benefits for cognition and quality of life for people with dementia. Most people received fewer than the recommended number of iCST sessions. Further research is needed to ascertain the clinical effectiveness of carer-led cognitive stimulation interventions for people with dementia. TRIAL REGISTRATION: Current Controlled Trials ISRCTN65945963. FUNDING: This project was funded by the National Institute of Health Research (NIHR) Health Technology Assessment (HTA) programme and will be published in full in Health Technology Assessment; Vol. 19, No. 64. See the NIHR Journals Library website for further information.

Entities:  

Mesh:

Year:  2015        PMID: 26292178      PMCID: PMC4781454          DOI: 10.3310/hta19640

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN: 1366-5278            Impact factor:   4.014


  15 in total

Review 1.  Cost-Utility Analyses of Interventions for Informal Carers: A Systematic and Critical Review.

Authors:  Wilfried Guets; Hareth Al-Janabi; Lionel Perrier
Journal:  Pharmacoeconomics       Date:  2020-04       Impact factor: 4.981

2.  Field-testing phase of the development of individual cognitive stimulation therapy (iCST) for dementia.

Authors:  Lauren A Yates; Vasiliki Orgeta; Phuong Leung; Aimee Spector; Martin Orrell
Journal:  BMC Health Serv Res       Date:  2016-07-08       Impact factor: 2.655

Review 3.  Health economic evaluations of non-pharmacological interventions for persons with dementia and their informal caregivers: a systematic review.

Authors:  Franziska Nickel; Janina Barth; Peter L Kolominsky-Rabas
Journal:  BMC Geriatr       Date:  2018-03-09       Impact factor: 3.921

4.  The impact of individual Cognitive Stimulation Therapy (iCST) on cognition, quality of life, caregiver health, and family relationships in dementia: A randomised controlled trial.

Authors:  Martin Orrell; Lauren Yates; Phuong Leung; Sujin Kang; Zoe Hoare; Chris Whitaker; Alistair Burns; Martin Knapp; Iracema Leroi; Esme Moniz-Cook; Stephen Pearson; Stephen Simpson; Aimee Spector; Steven Roberts; Ian Russell; Hugo de Waal; Robert T Woods; Vasiliki Orgeta
Journal:  PLoS Med       Date:  2017-03-28       Impact factor: 11.069

5.  Psychosocial therapy for Parkinson's-related dementia: study protocol for the INVEST randomised controlled trial.

Authors:  Sheree A McCormick; Kathryn R McDonald; Sabina Vatter; Vasiliki Orgeta; Ellen Poliakoff; Sarah Smith; Monty A Silverdale; Bo Fu; Iracema Leroi
Journal:  BMJ Open       Date:  2017-06-19       Impact factor: 2.692

6.  Missing data in trial-based cost-effectiveness analysis: An incomplete journey.

Authors:  Baptiste Leurent; Manuel Gomes; James R Carpenter
Journal:  Health Econ       Date:  2018-03-24       Impact factor: 3.046

7.  The Effect of Cognitive Intervention on Cognitive Improvement in Patients with Dementia.

Authors:  Kyunghwa Jo; Jin Hyeong Jhoo; Young-Ju Mun; Yeon Mi Kim; Sung Keun Kim; Seongheon Kim; Seung-Hwan Lee; Jae-Won Jang
Journal:  Dement Neurocogn Disord       Date:  2018-03-14

8.  The Quality of Carer-Patient Relationship Scale: Adaptation and Validation into Portuguese.

Authors:  Rosa Silva; Elzbieta Bobrowicz-Campos; Paulo Santos-Costa; Isabel Gil; Hugo Neves; João Apóstolo
Journal:  Int J Environ Res Public Health       Date:  2021-01-31       Impact factor: 3.390

9.  Cost-effectiveness of a non-pharmacological treatment vs. "care as usual" in day care centers for community-dwelling older people with cognitive impairment: results from the German randomized controlled DeTaMAKS-trial.

Authors:  Kathrin Steinbeisser; Larissa Schwarzkopf; Elmar Graessel; Hildegard Seidl
Journal:  Eur J Health Econ       Date:  2020-03-26

10.  What influences uptake of psychosocial interventions by people living with early dementia? A qualitative study.

Authors:  Becky Field; Elizabeth Coates; Gail Mountain
Journal:  Dementia (London)       Date:  2021-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.